Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

5 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

PORTAS2_Trial - Screening Visite

- 20/02/2023 - 4 Formulários, 20 Grupos de itens, 67 Elementos de dados, 1 Idioma
Grupos de itens: Einschluss, Einschlusskriterien, Ausschluss, Ausschlusskriterien, Biometrische Daten, Risikofaktoren, Raucher, Raucher, Vorerkrankungen / Voroperationen, Vorerkrankungen / Voroperationen, Vorerkrankungen / Voroperationen, Vorerkrankungen / Voroperationen, Vorerkrankungen / Voroperationen, Vorerkrankungen / Voroperationen, Vorerkrankungen / Voroperationen, Vorerkrankungen / Voroperationen, Vorerkrankungen / Voroperationen, Vorerkrankungen / Voroperationen, Vorerkrankungen / Voroperationen, Vorerkrankungen / Voroperationen
Portas2 P. Knebel1*, L. Fischer1*, J. Huesing2, R. Hennes1, K. Buhl1, M. W. Büchler1, C. M. Seiler1 Totally implantable access port in oncology patients:Success of implantation with and without the Seldinger technique through venae sectio - A randomized surgical trial (ISRCTN: 52368201)

OP Tag

4 Grupos de itens 27 Elementos de dados

Patientendokumentation

1 Grupo de itens 4 Elementos de dados

Follow-Up

5 Grupos de itens 14 Elementos de dados

GSK Eltrombopag Thrombocytopenia, Clinical Study ID: 105122 - Slit lamp, Biomicrosopy, Visual acuity and indirect ophthalmoscopy

- 12/12/2020 - 1 Formulário, 5 Grupos de itens, 26 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Data, slit lamp examination, slit lamp biomicroscopy, visual acuity, Indirect Ophtalmoscopy
The primary objective of this study was to demonstrate bioequivalence between eltrombopag oral film-coated tablets manufactured at Research and Development (R&D) and Commercial sites. The subject participants each went through two dosing periods (Period 1 and Period 2), during each of which they received a single dose of eltrombopag. The dosing periods were separated by a washout of at least 10 days. For each period, subjects had to perform a visit on the day before and one on the day of the administration of the drug. Furthermore, the protocol-defined visits included a screening visit and a follow-up visit. Study ID: 105122 Clinical Study ID: 105122 Study Title: Phase I Bioequivalence Study for SB 497115 GR Phase II and Phase III Tablets Sponsor: GlaxoSmithKline Phase: phase 1 Study Recruitment Status: Completed Generic Name: Eltrombopag Study Indication: Thrombocytopenia This form has to be filled out at the Screening and Follow-Up Visits.

REJUVENATE NCT02655419 - Screening Visit

- 24/01/2018 - 1 Formulário, 21 Grupos de itens, 212 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Information, Patient Information, Demography, Alcohol and Smoking History, Type of Substance, Eligibility determination, Failed IE criteria, Medical and surgical history, Medical / surgical event, Physical Examination, Physical examination, Diagnosis of Current Intra-Abdominal Infection, Site of Source of Infection, Radiological Examination, Infection-related Examination, Infection related Signs and Symptoms, Vital Signs examination, Temperature, Laboratory Tests, Laboratory Screening, Microbiology
A Phase IIa prospective, open-label, multicenter study to determine the pharmacokinetics (PK) and safety and tolerability of aztreonam-avibactam (ATM-AVI) for the treatment of complicated Intra-Abdominal Infections (cIAIs) in hospitalized adults. NCT02655419 Sponsors and Collaborators: Pfizer Innovative Medicines Initiative (IMI) COMBACTE-CARE Investigators: Study Director:Pfizer CT.gov Call Center;Pfizer Principal Investigator:Oliver Cornely;Clinical Trials Centre Cologne

Second cycle of therapy- BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With AML NCT01488344 - Second cycle of therapy

- 01/11/2017 - 1 Formulário, 10 Grupos de itens, 111 Elementos de dados, 1 Idioma
Grupos de itens: Physical examination, Medication: AraC, AraC Protocol, Medication: BIBF 1120, BIBF 1120 protocol, Haematology, Differential blood count, Clinical chemistry, Bone marrow examination, investigator signature
Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML) - NCT01488344 https://clinicaltrials.gov/ct2/show/NCT01488344 Principal Investigator PD Dr. Utz Krug RATIONALE: Low-dose cytarabine works in a minority of elderly patients with an acute myeloid leukemia unfit for intensive induction therapy by killing of leukemia cells. Addition of BIBF1120 to low-dose cytarabine might enhance the killing of leukemia cells. PURPOSE: This phase I / II trial is studying how safe BIBF1120 can be combined with low-dose cytarabine (phase I) and how well the combination of low-dose cytarabine and BIBF1120 works in elderly patients with acute myeloid leukemia unfit for intensive chemotherapy (phase II). Study Type: Interventional Study Design: Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Single-arm, Open Label, Multi-center Phase I/II Trial to Assess the Safety and Efficacy of BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With AML Unfit for an Intensive Induction Therapy

Second cycle of therapy- BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With AML NCT01488344 - Second cycle of therapy

- 01/11/2017 - 1 Formulário, 10 Grupos de itens, 111 Elementos de dados, 1 Idioma
Grupos de itens: Physical examination, Medication: AraC, AraC Protocol, Medication: BIBF 1120, BIBF 1120 protocol, Haematology, Differential blood count, Clinical chemistry, Bone marrow examination, investigator signature
Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML) - NCT01488344 https://clinicaltrials.gov/ct2/show/NCT01488344 Principal Investigator PD Dr. Utz Krug RATIONALE: Low-dose cytarabine works in a minority of elderly patients with an acute myeloid leukemia unfit for intensive induction therapy by killing of leukemia cells. Addition of BIBF1120 to low-dose cytarabine might enhance the killing of leukemia cells. PURPOSE: This phase I / II trial is studying how safe BIBF1120 can be combined with low-dose cytarabine (phase I) and how well the combination of low-dose cytarabine and BIBF1120 works in elderly patients with acute myeloid leukemia unfit for intensive chemotherapy (phase II). Study Type: Interventional Study Design: Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Single-arm, Open Label, Multi-center Phase I/II Trial to Assess the Safety and Efficacy of BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With AML Unfit for an Intensive Induction Therapy

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial